Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 5, 2011

Even Split on Whether Federal Circuit Will Change Akamai, McKesson Decisions

  • Voters are evenly divided, at 42.9%, on whether they think the Federal Circuit will change the standing infringement decisions for the Akamai and McKesson cases as a result of en banc arguments that occurred last month. The remaining 14.3% of respondents were undecided.

    Biopharma industry stakeholders are seeking clearer direction on when patents can be considered jointly infringed. Earlier this year, separate Federal Circuit panels held there was no viable legal theory to support findings that defendants in the two cases engaged in joint infringement, despite a contractual relationship in Akamai Technologies, Inc. v. Limelight Networks, Inc. and a doctor/patient relationship in McKesson Technologies Inc. v. Epic System Corp. Akamai and McKesson have won support from BIO, PhRMA, and Myriad Genetics, which all assert that current stipulations of joint infringement could be detrimental to personalized medicine.

Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »